ABBOTT LABORATORIES

ABT 10-Q · Q3 2025
API behind this page

ABT Q3 2025 request

Playground key active
Request URL /api/financials?ticker=ABT&year=2025&quarter=3
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric Q3 2025 Q3 2024 YoY
Revenue 11,369 10,635 +6.9%
Show Product Lines breakouts
COVID-19 Testing · Diagnostics 69 265 -74.0%
Show Business Segments breakouts
Diagnostics · Core Laboratory 1,364 1,314 +3.8%
Diagnostics · Molecular 131 128 +2.3%
Diagnostics · Non Us 1,367 1,380 -0.9%
Diagnostics · Non Us 998 982 +1.6%
Diagnostics · Non Us 95 91 +4.4%
Diagnostics · Non Us 47 43 +9.3%
Diagnostics · Non Us 227 264 -14.0%
Diagnostics · Operating Segments 2,253 2,412 -6.6%
Diagnostics · Point of Care 158 146 +8.2%
Diagnostics · Rapid Diagnostics 600 824 -27.2%
Diagnostics · US 886 1,032 -14.1%
Diagnostics · US 366 332 +10.2%
Diagnostics · US 36 37 -2.7%
Diagnostics · US 111 103 +7.8%
Diagnostics · US 373 560 -33.4%
Established Pharmaceuticals · Key Emerging Markets 1,097 994 +10.4%
Established Pharmaceuticals · Non Us 1,511 1,406 +7.5%
Established Pharmaceuticals · Non Us 1,097 994 +10.4%
Established Pharmaceuticals · Non Us 414 412 +0.5%
Established Pharmaceuticals · Operating Segments 1,511 1,406 +7.5%
Established Pharmaceuticals · Other 414 412 +0.5%
Medical Devices · Diabetes Care 2,057 1,725 +19.2%
Medical Devices · Electrophysiology 705 610 +15.6%
Medical Devices · Heart Failure 366 322 +13.7%
Medical Devices · Neuromodulation 254 236 +7.6%
Medical Devices · Non Us 2,927 2,531 +15.6%
Medical Devices · Non Us 1,261 1,052 +19.9%
Medical Devices · Non Us 383 325 +17.8%
Medical Devices · Non Us 86 70 +22.9%
Medical Devices · Non Us 58 46 +26.1%
Medical Devices · Non Us 336 309 +8.7%
Medical Devices · Non Us 338 288 +17.4%
Medical Devices · Non Us 465 441 +5.4%
Medical Devices · Operating Segments 5,448 4,747 +14.8%
Medical Devices · Rhythm Management 686 597 +14.9%
Medical Devices · Structural Heart 635 558 +13.8%
Medical Devices · US 2,521 2,216 +13.8%
Medical Devices · US 796 673 +18.3%
Medical Devices · US 322 285 +13.0%
Medical Devices · US 280 252 +11.1%
Medical Devices · US 196 190 +3.2%
Medical Devices · US 350 288 +21.5%
Medical Devices · US 297 270 +10.0%
Medical Devices · US 280 258 +8.5%
Medical Devices · Vascular 745 699 +6.6%
Nutritionals · Adult Nutritionals 1,176 1,111 +5.9%
Nutritionals · Non Us 1,265 1,116 +13.4%
Nutritionals · Non Us 808 729 +10.8%
Nutritionals · Non Us 457 387 +18.1%
Nutritionals · Operating Segments 2,153 2,066 +4.2%
Nutritionals · Pediatric Nutritionals 977 955 +2.3%
Nutritionals · US 888 950 -6.5%
Nutritionals · US 368 382 -3.7%
Nutritionals · US 520 568 -8.5%
Show Geography breakouts
Non Us 7,070 6,433 +9.9%
US 4,299 4,202 +2.3%
US · Corporate Non Segment 4 4 0.0%
Show Consolidation Items breakouts
Corporate Non Segment 4 4 0.0%
Operating Segments 11,365 10,631 +6.9%
Cost of Revenue 5,075 4,698 +8.0%
Show Business Segments breakouts
Diagnostics · Operating Segments 1,290 1,280 +0.8%
Established Pharmaceuticals · Operating Segments 714 644 +10.9%
Medical Devices · Operating Segments 1,767 1,605 +10.1%
Nutritionals · Operating Segments 1,223 1,151 +6.3%
Show Consolidation Items breakouts
Operating Segments 4,994 4,680 +6.7%
Total Costs & Expenses 9,312 8,776 +6.1%
Research & Development 766 713 +7.4%
Show Business Segments breakouts
Diagnostics · Operating Segments 150 165 -9.1%
Established Pharmaceuticals · Operating Segments 42 46 -8.7%
Medical Devices · Operating Segments 462 408 +13.2%
Nutritionals · Operating Segments 55 53 +3.8%
Show Consolidation Items breakouts
Operating Segments 709 672 +5.5%
Selling, General & Administrative 3,051 2,895 +5.4%
Show Business Segments breakouts
Diagnostics · Operating Segments 413 409 +1.0%
Established Pharmaceuticals · Operating Segments 364 336 +8.3%
Medical Devices · Operating Segments 1,390 1,221 +13.8%
Nutritionals · Operating Segments 515 550 -6.4%
Show Consolidation Items breakouts
Operating Segments 2,682 2,516 +6.6%
Operating Income 2,057 1,859 +10.7%
Show Business Segments breakouts
Diagnostics · Operating Segments 400 558 -28.3%
Established Pharmaceuticals · Operating Segments 391 380 +2.9%
Medical Devices · Operating Segments 1,829 1,513 +20.9%
Nutritionals · Operating Segments 360 312 +15.4%
Show Consolidation Items breakouts
Operating Segments 2,980 2,763 +7.9%
Interest Expense 121 142 -14.8%
Interest Income -77 -91 +15.4%
Other Non-Operating Income (Expense) -150 -121 -24.0%
Income Before Taxes 2,180 1,940 +12.4%
Income Tax Expense (Benefit) 536 294 +82.3%
Net Income 1,644 1,646 -0.1%
Show Equity Components breakouts
Retained Earnings 1,644 1,646 -0.1%
Comprehensive Income 1,536 1,977 -22.3%
Other Comprehensive Income -108 331 -132.6%
Show Equity Components breakouts
Accumulated Other Comprehensive Income -108 331 -132.6%
EPS (Basic) 0.94 0.94 0.0%
EPS (Diluted) 0.94 0.94 0.0%
Wtd Avg Shares (Basic) 1,742,142 1,739,466 +0.2%
Wtd Avg Shares (Diluted) 1,749,361 1,747,597 +0.1%
Foreign Currency Transaction Gain Loss Before Tax -17 -11 -54.5%
Net Income Loss Available To Common Stockholders Basic 1.6 1.6 0.0%

Balance Sheet

Balance Sheet
Metric Q3 2025 Q3 2024 YoY
Current Assets
Cash & Cash Equivalents 7,511 7,558 -0.6%
Short-Term Investments 222 230 -3.5%
Accounts Receivable 8,138 7,051 +15.4%
Inventory 6,708 6,813 -1.5%
Total Current Assets 24,839 23,802 +4.4%
Non-Current Assets
Property, Plant & Equipment 11,504 10,621 +8.3%
Goodwill 23,971 — —
Show Business Segments breakouts
Diagnostics 3.6 — —
Established Pharmaceuticals 2.7 — —
Medical Devices 17.4 — —
Nutritionals 285 — —
Total Assets 84,181 — —
Show Business Segments breakouts
Diagnostics · Operating Segments 8,201 — —
Established Pharmaceuticals · Operating Segments 3,730 — —
Medical Devices · Operating Segments 10,576 — —
Nutritionals · Operating Segments 4,891 — —
Show Consolidation Items breakouts
Operating Segments 27,398 — —
Long Term Investments 951 912 +4.3%
Show Fair Value By Measurement Basis breakouts
Carrying Reported Amount Fair Value Disclosure · Equity Securities 633 574 +10.3%
Carrying Reported Amount Fair Value Disclosure · Other Aggregated Investments 318 338 -5.9%
Estimate Of Fair Value Fair Value Disclosure · Equity Securities 633 574 +10.3%
Estimate Of Fair Value Fair Value Disclosure · Other Aggregated Investments 318 338 -5.9%
Show Investment Type breakouts
Equity Securities 633 574 +10.3%
Other Investments 318 338 -5.9%
Current Liabilities
Current Portion of Long-Term Debt 1,345 2,154 -37.6%
Total Current Liabilities 14,582 14,902 -2.1%
Non-Current Liabilities
Long-Term Debt 11,596 12,825 -9.6%
Long-Term Debt (Q) — — —
Show Fair Value By Measurement Basis breakouts
Carrying Reported Amount Fair Value Disclosure -12,941 — —
Estimate Of Fair Value Fair Value Disclosure -12,839 — —
Stockholders' Equity
Common Stock 25,412 25,020 +1.6%
Retained Earnings 49,103 39,056 +25.7%
Accumulated Other Comprehensive Income -6,684 -7,804 +14.4%
Total Stockholders' Equity 50,954 — —
Total Liabilities & Equity 84,181 74,356 +13.2%

Cash Flow Statement

Cash Flow Statement
Metric YTD Q3 2025 YTD Q3 2024 YoY
Operating Activities
Stock-Based Compensation 551 562 -2.0%
Change in Accounts Receivable -874 -533 -64.0%
Change in Inventory -39 -293 +86.7%
Net Cash from Operations 6,251 5,690 +9.9%
Investing Activities
Capital Expenditures -1,482 -1,487 +0.3%
Other Investing Activities 12 5 +140.0%
Net Cash from Investing -1,509 -1,472 -2.5%
Financing Activities
Share Repurchases -591 -980 +39.7%
Net Cash from Financing -4,912 -3,543 -38.6%
Other Cash Flow
Net Change in Cash -105 662 -115.9%

Values in millions USD. Source: SEC EDGAR 10-Q filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key